Inhibrx Biosciences, Inc

INBX · United States

Share price · INBX

$69.06-25.56 (-27.01%) 3M

close as of 2026-11-18 · 24h delayed · vol 289K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INBX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+12.4%
  2. 28 Oct 2026-23.4%
  3. 25 Aug 2026+16.9%
  4. 14 Aug 2026-8.9%
  5. 12 Aug 2026+6.5%
  6. 12 May 2026-14.8%
  7. 22 Apr 2026+36.9%
  8. 9 Apr 2026+12.8%

    Nothing announced by INBX that day or the session before.

  9. 27 Mar 2026-11.2%
  10. 19 Mar 2026-5.6%

Share of unusual movement by asset

For each asset, the share of INBX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
ozekibart
events and moves
860%
Ordastobart
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—3%
Sessions with no dated event—35%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
OX40 (agonist)Monoclonal antibody
Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
Phase 2
DR5 (TRAIL-R2)Other
Bone Cancer
Conventional Chondrosarcoma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
OrdastobartPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-02-28 · NCT06623136 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
OrdastobartPhase 2/3Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Est. primary completion 2029-12 · NCT06295731 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
OrdastobartPhase 1/2Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma …
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

14 April 2027FDA action dateozekibartPDUFA goal date set for April 14, 2027
US, FDA · Source ↗

Recent

8 September 2026Topline resultINBRX-106Phase 2 portion of NCT06295731: INBRX-106 + pembrolizumab confirmed ORR 48.3% vs 26.5% (primary endpoint analysis)
Inhibrx Biosciences · Source ↗
15 June 2026Filing acceptedozekibartFDA accepts the ozekibart BLA in conventional chondrosarcoma (PDUFA goal date 14 April 2027)
US, FDA · Inhibrx Biosciences, Inc. · Source ↗
23 October 2025Topline resultozekibartRegistrational ChonDRAgon trial of ozekibart met its primary endpoint (PFS)
Inhibrx Biosciences, Inc · Source ↗
21 January 2025Topline resultozekibartPreliminary Phase 1 data for ozekibart plus FOLFIRI in colorectal cancer

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$2.0M$26M$199M$39M-$35M operating cash flowreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$24M$133M$37M-$30M operating cash flowreport ↗
2026-Q1—$25M$162M$33M-$38M operating cash flowreport ↗
2025-Q3$0$29M$153M$35M-$34M operating cash flowreport ↗
2025-Q2$1.3M$22M$187M$29M-$30M operating cash flowreport ↗
2025-Q1$0$37M$217M$43M-$36M operating cash flowreport ↗
2024-Q3$0$39M$196M$44M-$30M operating cash flowreport ↗
2024-Q2$0.1M$68M$227M—-$57M operating cash flowreport ↗
2024-Q1$0$64M$252M$79M-$63M operating cash flowreport ↗
2023-Q3$0.1M$38M$337M$52M-$54M operating cash flowreport ↗
2023-Q2<$0.1M$34M$192M$47Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.3M$113M$124M$35M-$130M operating cash flowreport ↗

Inhibrx Biosciences reported revenue of $1.3M for fiscal 2025, up 550.0% YoY from $0.2M, with R&D spend of $113.03M, down 44.5% YoY from $203.74M. Cash and equivalents were $124.22M at year-end, and the company reported a net loss of $140.05M with a quarterly net burn of $140.06M.

During the year, the company advanced ozekibart, with the ChonDRAgon trial meeting its primary endpoint in chondrosarcoma and a biologics license application planned for early the second quarter of 2026. It also plans FDA discussions in the second half of 2026 regarding potential accelerated approval pathways in colorectal cancer and Ewing sarcoma, subject to ongoing data trends. For INBRX-106, enrollment was completed in the checkpoint-inhibitor-refractory NSCLC cohort and in the Phase 2 portion of the HNSCC trial, with initial Phase 2 results expected in the second quarter of 2026 and PFS data planned for the fourth quarter of 2026.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.2M$204M$153M—-$194M operating cash flowreport ↗
2023-FY$1.8M$192M$278M$60M-$193M operating cash flowreport ↗
2022-FY——$274M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 20 purchases ($6.3M), 5 sales ($279K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-14Lappe Mark · director, Chief Executive OfficerOpen-market purchase2,470$84.07$208KForm 4
2026-10-14Lappe Mark · director, Chief Executive OfficerOpen-market purchase2,470$85.00$210KForm 4
2026-10-14Lappe Mark · director, Chief Executive OfficerOpen-market purchase100$85.76$9KForm 4
2026-10-14Lappe Mark · director, Chief Executive OfficerOpen-market purchase2,449$84.07$206KForm 4
2026-10-14Lappe Mark · director, Chief Executive OfficerOpen-market purchase2,451$85.00$208KForm 4
2026-10-14Lappe Mark · director, Chief Executive OfficerOpen-market purchase100$85.76$9KForm 4
2026-09-28Lappe Mark · director, Chief Executive OfficerOpen-market purchase1,500$98.88$148KForm 4
2026-09-28Lappe Mark · director, Chief Executive OfficerOpen-market purchase3,000$101.70$305KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 135 reporting institutions held 12.7M shares ($853.7M, 86.1% of shares outstanding).

#InstitutionSharesValue
1PERCEPTIVE ADVISORS LLC1,442,707$97.0M
2VIKING GLOBAL INVESTORS LP1,437,705$96.7M
3MORGAN STANLEY1,263,078$84.9M
4Sanofi1,157,926$77.8M
5HighTower Advisors, LLC870,200$58.5M
6BlackRock, Inc.798,898$53.7M
7STATE STREET CORP550,845$37.0M
8VANGUARD CAPITAL MANAGEMENT LLC486,422$32.7M
9Sofinnova Investments, Inc.406,029$27.3M
10Capital Research Global Investors392,847$26.4M
11Woodline Partners LP384,433$25.8M
12MILLENNIUM MANAGEMENT LLC327,860$22.0M
13PFM Health Sciences, LP305,431$20.5M
14Schonfeld Strategic Advisors LLC254,827$17.1M
15GEODE CAPITAL MANAGEMENT, LLC231,509$15.6M